Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA
SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced that the New Drug Application (NDA) for its core product, zemprocitinib capsules, for the treatment of moderate-to-severe atopic dermatitis (AD), has been formally […]





